BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25487607)

  • 1. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
    Boligan KF; Mesa C; Fernandez LE; von Gunten S
    Cell Mol Life Sci; 2015 Apr; 72(7):1231-48. PubMed ID: 25487607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology.
    Hugonnet M; Singh P; Haas Q; von Gunten S
    Front Immunol; 2021; 12():799861. PubMed ID: 34975914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycan-Lectin Interactions in Cancer and Viral Infections and How to Disrupt Them.
    Kremsreiter SM; Kroell AH; Weinberger K; Boehm H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation in health and disease.
    Reily C; Stewart TJ; Renfrow MB; Novak J
    Nat Rev Nephrol; 2019 Jun; 15(6):346-366. PubMed ID: 30858582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho GTPase Rac1: molecular switch within the galectin network and for N-glycan α2,6-sialylation/O-glycan core 1 sialylation in colon cancer in vitro.
    André S; Singh T; Lacal JC; Smetana K; Gabius HJ
    Folia Biol (Praha); 2014; 60(3):95-107. PubMed ID: 25056432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour suppressor p16(INK4a) - anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model.
    Amano M; Eriksson H; Manning JC; Detjen KM; André S; Nishimura S; Lehtiö J; Gabius HJ
    FEBS J; 2012 Nov; 279(21):4062-80. PubMed ID: 22943525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine.
    Padler-Karavani V
    Cancer Lett; 2014 Sep; 352(1):102-12. PubMed ID: 24141190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
    Smith BAH; Bertozzi CR
    Nat Rev Drug Discov; 2021 Mar; 20(3):217-243. PubMed ID: 33462432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor.
    Lee A; Chick JM; Kolarich D; Haynes PA; Robertson GR; Tsoli M; Jankova L; Clarke SJ; Packer NH; Baker MS
    Mol Cell Proteomics; 2011 Sep; 10(9):M900538MCP200. PubMed ID: 20167946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-mediated regulation of immune cell function in disease.
    Macauley MS; Crocker PR; Paulson JC
    Nat Rev Immunol; 2014 Oct; 14(10):653-66. PubMed ID: 25234143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer.
    Cagnoni AJ; Pérez Sáez JM; Rabinovich GA; Mariño KV
    Front Oncol; 2016; 6():109. PubMed ID: 27242953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycan changes: cancer metastasis and anti-cancer vaccines.
    Li M; Song L; Qin X
    J Biosci; 2010 Dec; 35(4):665-73. PubMed ID: 21289447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.
    Badr HA; AlSadek DM; Mathew MP; Li CZ; Djansugurova LB; Yarema KJ; Ahmed H
    Biomaterials; 2015 Nov; 70():23-36. PubMed ID: 26295436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered tumor-cell glycosylation promotes metastasis.
    Häuselmann I; Borsig L
    Front Oncol; 2014; 4():28. PubMed ID: 24592356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialylation of N-glycans: mechanism, cellular compartmentalization and function.
    Bhide GP; Colley KJ
    Histochem Cell Biol; 2017 Feb; 147(2):149-174. PubMed ID: 27975143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycan Chains of Gangliosides: Functional Ligands for Tissue Lectins (Siglecs/Galectins).
    Ledeen RW; Kopitz J; Abad-Rodríguez J; Gabius HJ
    Prog Mol Biol Transl Sci; 2018; 156():289-324. PubMed ID: 29747818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.